<p>For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence 2026), held from No</p>